Live feed07:30:00·989dPRReleasevia QuantisnowAlnylam Announces Receipt of Complete Response Letter from U.S. FDA for Supplemental New Drug Application for Patisiran for the Treatment of the Cardiomyopathy of ATTR AmyloidosisByQuantisnow·Wall Street's wire, on your screen.ALNY· Alnylam Pharmaceuticals Inc.Health Care
